Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
This article was originally published in Pharmaceutical Approvals Monthly
Clinically speaking, Roche/Genentech’s injectable Lucentis (ranibizumab) looks well-positioned for a role in diabetic macular edema after the full release of Phase III trial data.
You may also be interested in...
In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.
The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.